CO2021010882A2 - 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión - Google Patents
5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresiónInfo
- Publication number
- CO2021010882A2 CO2021010882A2 CONC2021/0010882A CO2021010882A CO2021010882A2 CO 2021010882 A2 CO2021010882 A2 CO 2021010882A2 CO 2021010882 A CO2021010882 A CO 2021010882A CO 2021010882 A2 CO2021010882 A2 CO 2021010882A2
- Authority
- CO
- Colombia
- Prior art keywords
- disorder
- dimethyltryptamine
- dmt
- meo
- depression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan composiciones para su uso en el tratamiento de un paciente que padece un trastorno mental en particular trastorno depresivo mayor, trastorno depresivo persistente, trastorno de ansiedad, trastorno de estrés postraumático, trastorno dismórfico corporal, trastorno obsesivo compulsivo, trastorno alimentario y abuso de sustancias psicoactivas. Se proporcionan además regímenes de dosificación para tratar estos trastornos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19158774 | 2019-02-22 | ||
| PCT/EP2020/054803 WO2020169850A1 (en) | 2019-02-22 | 2020-02-24 | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021010882A2 true CO2021010882A2 (es) | 2022-01-17 |
Family
ID=65529503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0010882A CO2021010882A2 (es) | 2019-02-22 | 2021-08-18 | 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20220071958A1 (es) |
| EP (3) | EP3927337B8 (es) |
| JP (1) | JP2022521337A (es) |
| KR (1) | KR20210154966A (es) |
| CN (1) | CN114555078A (es) |
| AU (1) | AU2020225410A1 (es) |
| BR (1) | BR112021016153A2 (es) |
| CA (1) | CA3130406A1 (es) |
| CL (1) | CL2021002174A1 (es) |
| CO (1) | CO2021010882A2 (es) |
| CR (1) | CR20210437A (es) |
| DK (1) | DK3927337T3 (es) |
| DO (1) | DOP2021000176A (es) |
| EA (1) | EA202192318A1 (es) |
| EC (1) | ECSP21060868A (es) |
| FI (1) | FI3927337T3 (es) |
| HR (1) | HRP20240532T1 (es) |
| IL (1) | IL285537A (es) |
| LT (1) | LT3927337T (es) |
| MA (1) | MA55021B1 (es) |
| MX (1) | MX2021009941A (es) |
| NI (1) | NI202100080A (es) |
| PE (1) | PE20220015A1 (es) |
| PL (1) | PL3927337T3 (es) |
| PT (1) | PT3927337T (es) |
| SI (1) | SI3927337T1 (es) |
| WO (1) | WO2020169850A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020169850A1 (en) | 2019-02-22 | 2020-08-27 | Gh Research Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP3753923A1 (en) * | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| WO2021089873A1 (en) | 2019-11-07 | 2021-05-14 | Small Pharma Ltd | Method of synthesis |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| EP4153564A4 (en) | 2020-05-19 | 2024-06-19 | Cybin IRL Limited | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| WO2021250434A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| US20220040150A1 (en) * | 2020-08-05 | 2022-02-10 | Universitatsspital Basel | Intravenous dmt administration method for dmt-assisted psychotherapy |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| MX2022014128A (es) * | 2020-08-28 | 2023-02-14 | Small Pharma Ltd | Formulacion inyectable. |
| EP4221682A2 (en) * | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| CN112138028A (zh) * | 2020-10-10 | 2020-12-29 | 南京中医药大学 | 蟾蜍色胺类物质在制备抗抑郁药物中的应用 |
| WO2022082058A1 (en) * | 2020-10-16 | 2022-04-21 | Eleusis Therapeutics Us, Inc. | Method of treatment by tryptamine alkaloids |
| EP4255421A1 (en) * | 2020-12-01 | 2023-10-11 | Small Pharma Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| CA3113414A1 (en) * | 2021-03-29 | 2022-09-29 | Mind Cure Health Inc. | Psychedelics protocol computer systems and methods |
| US11602521B2 (en) | 2021-04-26 | 2023-03-14 | ATAI Life Sciences AG | N,N-dimethyltryptamine compositions and methods |
| WO2022235927A1 (en) * | 2021-05-05 | 2022-11-10 | Gilgamesh Pharmaceuticals, Inc. | Novel tryptamines and methods of treating mood disorders |
| EP4352043A1 (en) | 2021-06-09 | 2024-04-17 | ATAI Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| AU2022393234A1 (en) * | 2021-11-18 | 2024-06-06 | Cybin Uk Ltd | Injectable and inhalable formulations |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023168022A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocybin |
| WO2023186798A1 (en) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-meo-dmt for use in the treatment of sleep disturbance |
| RS65585B1 (sr) | 2022-03-27 | 2024-06-28 | Gh Res Ireland Limited | Kristalna so 5-meo-dmt hidrobromid |
| WO2023186826A1 (en) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-meo-dmt for use in the treatment of postpartum depression |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| WO2024160390A1 (en) | 2023-01-30 | 2024-08-08 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression |
| WO2024160391A1 (en) | 2023-01-30 | 2024-08-08 | GH Research Ireland Limited | Treatment of mental disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| CA2526475A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| ATE489981T1 (de) | 2006-08-01 | 2010-12-15 | Stobi Gmbh & Co Kg | Ventilballon für inhalatoren |
| CN103816150A (zh) * | 2014-03-14 | 2014-05-28 | 兰州理工大学 | 山蚂蝗生物碱单体成分的用途 |
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| WO2020169850A1 (en) | 2019-02-22 | 2020-08-27 | Gh Research Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
-
2020
- 2020-02-24 WO PCT/EP2020/054803 patent/WO2020169850A1/en active Application Filing
- 2020-02-24 CN CN202080030317.3A patent/CN114555078A/zh active Pending
- 2020-02-24 EP EP20710059.5A patent/EP3927337B8/en active Active
- 2020-02-24 PE PE2021001360A patent/PE20220015A1/es unknown
- 2020-02-24 EA EA202192318A patent/EA202192318A1/ru unknown
- 2020-02-24 HR HRP20240532TT patent/HRP20240532T1/hr unknown
- 2020-02-24 MX MX2021009941A patent/MX2021009941A/es unknown
- 2020-02-24 AU AU2020225410A patent/AU2020225410A1/en active Pending
- 2020-02-24 EP EP24157425.0A patent/EP4349407A3/en active Pending
- 2020-02-24 PL PL20710059.5T patent/PL3927337T3/pl unknown
- 2020-02-24 JP JP2021549427A patent/JP2022521337A/ja active Pending
- 2020-02-24 FI FIEP20710059.5T patent/FI3927337T3/fi active
- 2020-02-24 DK DK20710059.5T patent/DK3927337T3/da active
- 2020-02-24 US US17/431,626 patent/US20220071958A1/en not_active Abandoned
- 2020-02-24 BR BR112021016153-8A patent/BR112021016153A2/pt unknown
- 2020-02-24 PT PT207100595T patent/PT3927337T/pt unknown
- 2020-02-24 SI SI202030414T patent/SI3927337T1/sl unknown
- 2020-02-24 LT LTEPPCT/EP2020/054803T patent/LT3927337T/lt unknown
- 2020-02-24 MA MA55021A patent/MA55021B1/fr unknown
- 2020-02-24 CA CA3130406A patent/CA3130406A1/en active Pending
- 2020-02-24 EP EP24157388.0A patent/EP4353314A3/en active Pending
- 2020-02-24 KR KR1020217030215A patent/KR20210154966A/ko unknown
- 2020-02-24 CR CR20210437A patent/CR20210437A/es unknown
-
2021
- 2021-08-11 IL IL285537A patent/IL285537A/en unknown
- 2021-08-16 CL CL2021002174A patent/CL2021002174A1/es unknown
- 2021-08-17 EC ECSENADI202160868A patent/ECSP21060868A/es unknown
- 2021-08-18 CO CONC2021/0010882A patent/CO2021010882A2/es unknown
- 2021-08-20 DO DO2021000176A patent/DOP2021000176A/es unknown
- 2021-08-20 NI NI202100080A patent/NI202100080A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA55021B1 (fr) | 2024-05-31 |
| EP3927337B8 (en) | 2024-03-20 |
| NI202100080A (es) | 2021-12-06 |
| JP2022521337A (ja) | 2022-04-06 |
| EA202192318A1 (ru) | 2021-12-21 |
| MA55021A (fr) | 2021-12-29 |
| LT3927337T (lt) | 2024-07-10 |
| WO2020169850A1 (en) | 2020-08-27 |
| PT3927337T (pt) | 2024-05-17 |
| DK3927337T3 (da) | 2024-04-22 |
| CL2021002174A1 (es) | 2022-01-28 |
| EP4349407A3 (en) | 2024-07-03 |
| AU2020225410A1 (en) | 2021-08-19 |
| PE20220015A1 (es) | 2022-01-11 |
| IL285537A (en) | 2021-09-30 |
| EP4353314A2 (en) | 2024-04-17 |
| MX2021009941A (es) | 2021-12-10 |
| EP4353314A3 (en) | 2024-07-03 |
| EP3927337B1 (en) | 2024-02-14 |
| BR112021016153A2 (pt) | 2021-10-05 |
| KR20210154966A (ko) | 2021-12-21 |
| US20220071958A1 (en) | 2022-03-10 |
| PL3927337T3 (pl) | 2024-07-29 |
| CA3130406A1 (en) | 2020-08-27 |
| ECSP21060868A (es) | 2021-11-30 |
| SI3927337T1 (sl) | 2024-07-31 |
| DOP2021000176A (es) | 2021-11-21 |
| CN114555078A (zh) | 2022-05-27 |
| CR20210437A (es) | 2021-11-02 |
| EP3927337A1 (en) | 2021-12-29 |
| FI3927337T3 (fi) | 2024-05-08 |
| EP4349407A2 (en) | 2024-04-10 |
| HRP20240532T1 (hr) | 2024-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021010882A2 (es) | 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión | |
| CO2021010883A2 (es) | Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales | |
| NI201700137A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicaciãn viral del dengue | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| AR054371A1 (es) | Metodos y composiciones para manejo de desordenes psicoticos | |
| CO2019013042A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| CU20120034A7 (es) | Compuestos y composiciones como inhibidores de cinasa de proteína | |
| CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019012035A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2022010592A2 (es) | Métodos de tratamiento de la esplenomegalia | |
| UY38506A (es) | Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotrofica | |
| AR048370A1 (es) | Composicion para mejorar funciones cognitivas y la memoria | |
| EA201990602A3 (ru) | Комбинации пальмитоилэтаноламида для лечения хронической боли | |
| AR122059A1 (es) | Usos y formulaciones de cannabinoides | |
| EA201990976A1 (ru) | Новый способ профилактического лечения непроизвольной потери массы | |
| CO2021005797A2 (es) | Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia | |
| BR112018009476A2 (pt) | regime de dosagem de plasminogênio para cicatrização de ferimentos | |
| BR112018015483A2 (pt) | formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona | |
| AR117577A1 (es) | Un fármaco para el tratamiento de trastornos en la función de un órgano o tejido y las enfermedades acompañadas por estos trastornos, y un método para obtenerlo | |
| BR112020014583A8 (pt) | Composição para tratar um paciente que sofre de colite ulcerosa e uso da composição como um fármaco | |
| EA201892830A1 (ru) | Применение ксиборнола в качестве активного агента для лечения вирусных инфекций | |
| MX2022009776A (es) | Tratamiento de la colangitis biliar primaria con elafibranor. | |
| AR117329A1 (es) | Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica |